MSC therapy is where the most patient confusion, the most aggressive marketing, and the sharpest regulatory line all meet. Straight answers do more for a practice's credibility than any brochure. Here they are.
Case walkthrough: a patient considering treatment abroad
Amir, 55, has bilateral knee osteoarthritis. He has heard about a clinic in Panama offering "50 million allogeneic MSCs" per infusion. His U.S. clinician offers a BMAC procedure combined with ECSWT and HPLT sequencing under current U.S. framing. The two of them spend 20 minutes talking through the evidence base, the regulatory difference, the cost differential, and the follow-up realities. Amir chooses the U.S. same-day procedure and reports meaningful functional improvement at 6 months. The clinician did not need to disparage the overseas option — an honest, transparent conversation was enough.
Twenty questions patients ask
1. What are MSCs?
Mesenchymal stem/stromal cells — a signaling cell population found in bone marrow, fat, umbilical cord, and other tissues. They release growth factors, modulate inflammation, and support tissue repair.
2. Are MSC therapies legal in the U.S.?
Same-day autologous minimally manipulated MSC preparations (like BMAC) are legal. Culture-expanded MSC therapy is investigational and requires an FDA IND.
3. Why can I get culture-expanded MSC therapy abroad?
Other countries operate under different regulatory schemes. Some have clear registration paths; some are less regulated. Quality varies widely.
4. Is going abroad safe?
It depends entirely on the specific clinic, jurisdiction, and product. Look for certified facilities, published outcome data, characterization certificates, and transparent follow-up. Be very skeptical of clinics that promise systemic anti-aging.
5. What can MSCs treat?
Same-day autologous BMAC has supportive evidence for knee OA, non-union fractures, early femoral head osteonecrosis, and select wound care. Approved MSC-based products exist internationally for graft-vs-host disease and perianal Crohn's fistulas.
6. What can MSCs not treat?
Autism, ALS, cerebral palsy, autoimmune disease reversal, and generic anti-aging are not supported by high-quality evidence and typically fall outside U.S. legal framing.
7. Is IV MSC infusion effective?
The evidence is limited and the mechanism is transient — IV MSCs are trapped in the lungs and cleared within days. Some short-term paracrine effect is plausible; systemic regeneration is not established.
8. Are MSCs the same as embryonic stem cells?
No. MSCs are adult (or perinatal) tissue-derived cells. There are no embryonic cells involved in current MSC therapies.
9. Where do the cells come from in a U.S. procedure?
Your own bone marrow (iliac crest) or adipose tissue.
10. Does the harvest hurt?
Manageable with local anesthesia; 24–72 hours of soreness afterward.
11. How many treatments?
Usually one procedure, with periodic device or PRP maintenance.
12. When will I see results?
6–12 weeks for symptom shifts; peak at 6 months.
13. How much does it cost?
$4,000–$8,000 in the U.S. for BMAC-based joint therapy. International culture-expanded MSC therapy can range from $10,000 to $50,000+ including travel.
14. Is it covered by insurance?
Rarely.
15. Are there any side effects?
Harvest-site soreness, procedural risks (bleeding, infection), and transient increased joint pain in the first 1–2 weeks. Serious complications are rare.
16. What are the red flags in a clinic?
Vague or evasive answers about cell source, processing, and regulatory framing. Cell counts of "billions" from same-day preparations. Systemic anti-aging claims. Refusal to provide written outcomes data.
17. Do I need to stop any medications?
NSAIDs before and after; discuss anti-coagulants with the prescribing physician.
18. Can I combine MSC therapy with other regenerative treatments?
Yes — device pairing (ECSWT, HPLT) is standard; PRP as maintenance is common.
19. Are results permanent?
The therapeutic shift is durable, but degeneration continues its underlying trajectory. Maintenance improves durability.
20. What questions should I ask a provider?
What is the tissue source? How is the product prepared? What is the regulatory framing? What outcomes do you track? Can I see published data on your protocol? A good provider welcomes these questions.